Chinese company completes acquisition of US firm providing immunotherapy for prostate cancer – Xinhua
|
Chinese company completes acquisition of US firm providing immunotherapy for prostate cancer
Xinhua At the heart of the deal is Dendreon’s lead product, Provenge, the only cellular immunotherapy approved so far by the U.S. Food and Drug Administration (FDA) for treatment of asymptomatic or minimally symptomatic metastatic castration-resistant … |
Investor’s Business Daily |
How These Drugmakers Are Making Science Fiction A Reality In Cancer
Investor’s Business Daily “CAR–T is the best form of immuno-oncology,” according to Janney analyst Debjit Chattopadhyay. Immuno-oncology drugs harness the immune system to treat cancer. To create the drug, researchers extract the immune system cells from a patient’s blood. |
|
€40M in Series C for a British Biotech Treating Blindness with Gene Therapy
Labiotech.eu (blog) NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the … |
|
€40M in Series C for a British Biotech Treating Blindness with Gene Therapy
Labiotech.eu (blog) NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the clinic, the company has closed a Series C round with $45M (€39.5M) that will go towards … |
|
NightstaRx Raises $45M to Fund Phase III Study with Retinal Disease Gene Therapy
Genetic Engineering & Biotechnology News (blog) U.K. firm NightstaRx raised $45 million in a Series C financing round to support continued clinical development of its pipeline of retinal gene therapies, including a pending Phase III study with lead candidate NSR-REP1 for treating choroideremia. The … |